Amplia Therapeutics Enters Second Phase of Research Collaboration with South Korean Preclinical Drug Screening Firm

MT Newswires Live12-19 09:54

Amplia Therapeutics (ASX:ATX) entered into the second phase of a research collaboration with South Korean preclinical drug screening company Next & Bio, according to a Friday Australian bourse filing.

The firms are collaborating on investigating the ability of Amplia's FAK inhibitors to suppress the growth of patient-derived pancreatic cancer cells that possess genetic mutations in the kRAS gene, which are known to be present in over 90% of pancreatic cancers.

Amplia's FAK inhibitor narmafotinib showed promising activity in initial tests, per the filing. Further studies investigating the activity of a combination of narmafotinib with known inhibitors of the mutant kRAS gene will be conducted.

Its shares rose 2% in recent trading on Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592136767?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 09:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592136767","market":"nz","top_or_hot":-1,"title":"Amplia Therapeutics Enters Second Phase of Research Collaboration with South Korean Preclinical Drug Screening Firm","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) entered into the second phase of a research collaboration with South Korean preclinical drug screening company Next &amp; Bio, according to a Friday Australian bourse filing.</p><p>The firms are collaborating on investigating the ability of Amplia's FAK inhibitors to suppress the growth of patient-derived pancreatic cancer cells that possess genetic mutations in the kRAS gene, which are known to be present in over 90% of pancreatic cancers.</p><p>Amplia's FAK inhibitor narmafotinib showed promising activity in initial tests, per the filing. Further studies investigating the activity of a combination of narmafotinib with known inhibitors of the mutant kRAS gene will be conducted.</p><p>Its shares rose 2% in recent trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amplia Therapeutics Enters Second Phase of Research Collaboration with South Korean Preclinical Drug Screening Firm</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmplia Therapeutics Enters Second Phase of Research Collaboration with South Korean Preclinical Drug Screening Firm\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-19 09:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) entered into the second phase of a research collaboration with South Korean preclinical drug screening company Next &amp; Bio, according to a Friday Australian bourse filing.</p><p>The firms are collaborating on investigating the ability of Amplia's FAK inhibitors to suppress the growth of patient-derived pancreatic cancer cells that possess genetic mutations in the kRAS gene, which are known to be present in over 90% of pancreatic cancers.</p><p>Amplia's FAK inhibitor narmafotinib showed promising activity in initial tests, per the filing. Further studies investigating the activity of a combination of narmafotinib with known inhibitors of the mutant kRAS gene will be conducted.</p><p>Its shares rose 2% in recent trading on Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2592136767","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592136767","pubTimestamp":1766109250,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amplia Therapeutics  entered into the second phase of a research collaboration with South Korean preclinical drug screening company Next & Bio, according to a Friday Australian bourse filing.The firms are collaborating on investigating the ability of Amplia's FAK inhibitors to suppress the growth of patient-derived pancreatic cancer cells that possess genetic mutations in the kRAS gene, which are known to be present in over 90% of pancreatic cancers.Amplia's FAK inhibitor narmafotinib showed promising activity in initial tests, per the filing. Further studies investigating the activity of a combination of narmafotinib with known inhibitors of the mutant kRAS gene will be conducted.Its shares rose 2% in recent trading on Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","ATX.AU":"AMPLIA THERAPEUTICS LTD","BK7067":"生物科技","BK4007":"制药","LENZ":"Therapeutics"},"translate_title":"Amplia Therapeutics与韩国临床前药物筛选公司进入第二阶段研究合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATX.AU":1,"LENZ":1.5},"content_text":"Amplia Therapeutics (ASX:ATX) entered into the second phase of a research collaboration with South Korean preclinical drug screening company Next & Bio, according to a Friday Australian bourse filing.The firms are collaborating on investigating the ability of Amplia's FAK inhibitors to suppress the growth of patient-derived pancreatic cancer cells that possess genetic mutations in the kRAS gene, which are known to be present in over 90% of pancreatic cancers.Amplia's FAK inhibitor narmafotinib showed promising activity in initial tests, per the filing. Further studies investigating the activity of a combination of narmafotinib with known inhibitors of the mutant kRAS gene will be conducted.Its shares rose 2% in recent trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592136767","isCrawlerRequest":true}